Compare AMETEK, Inc. (AME) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? AMETEK, Inc. trades at $260 (market cap $58.76B), while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: AMETEK, Inc. pays a 0.53% dividend while State Street SPDR S&P Biotech ETF pays none, and AMETEK, Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| AME | XBI | |
|---|---|---|
Market Cap | $58.76B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $256.30 | $164.28 |
52-Week Low | $179.28 | $86.92 |
Enterprise Value | $60.30B | — |
Dividend Yield | 0.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $258.62, up 2.27% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The company reported record Q2 results and raised full-year guidance, supported by robust revenue growth and a 20.04% net income margin. Analysts maintain a consensus buy rating with a $281.86 price target, reflecting optimism about its 3D printing and electronics testing segments.
The outlook is positive given consistent earnings beats and upward guidance, but risks include high valuation multiples (P/E 37.47) and exposure to macroeconomic volatility. Institutional sentiment remains strong, with no sell ratings among 30 analysts, though the stock's proximity to resistance at $261 warrants caution for near-term entries.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
